In search of novel ways to modulate the PI3K pathway for therapeutic benefit

Speaker Professor Bart Vanhaesebroeck, Cell Signalling, UCL Cancer Institute

Title In search of novel ways to modulate the PI3K pathway for therapeutic benefit

Host Faruk Ramadani

 

Abstract The PI3K pathway is frequently genetically activated in cancer and is involved in immune dysregulation. The clinical development of PI3K inhibitors has proven challenging, with progress hampered by poor drug tolerance, intrinsic and acquired drug resistance and signalling feedback loops that neutralize PI3K inhibition. I will provide a general overview of PI3K targeting in disease, and provide an update on our efforts to explore alternative ways to modulate the PI3K pathway, including in cancer immunotherapy, cancer prevention, and the generation of small molecule activators of PI3K.